SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins the later rounds of HAX and IndieBio graduates.  HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

SOSV

IndieBio is the world’s first accelerator devoted to startups using biology to solve the world's largest problems. IndieBio is an SOSV program. SOSV is a global venture capital firm that operates startup accelerator investment programs. At the close of 2020, SOSV had more than 1,000 portfolio companies and $855 million in assets under management.

IndieBio

Marinya Capital is the family office of a branch of the Fairfax family. It was originally established by Fairfax media, a large Australian media company. Marinya holds active property investments and a portfolio of investments into fund managers. Marinya Capital also makes direct private equity and venture capital investments into select opportunities.

Marinya Capital

Zero Carbon Capital is on a mission to accelerate the zero carbon transition through investment in pre-seed and seed climate tech companies in the UK and Europe.  We are looking for scientific, hardware innovations and vision-aligned, ambitious teams that are addressing unsolved emissions areas of at least 0.5Gt of CO2e per year by 2050.

Zero Carbon Capital

Spectrum Impact is a family office committed to solving large-scale societal problems with novel solutions. We allocate the for-profit and not-for-profit pools of capital in a manner consistent with the objective of optimizing the financial, societal, and environmental returns on the investments made.

Spectrum Impact

MANDI is an early-stage venture capital fund focused on accelerating the adoption of disruptive technologies in the food and agriculture industries. From our offices in Latin America and Europe, we invest in start-ups that are reshaping how we produce and consume food. Our global network of industry leaders and our business expertise help founders accelerate the development and commercialization of next-generation technologies.

Mandi Ventures

Asahi Kasei Corporation provides solutions based in chemistry and materials science to a range of markets, including fibers, chemicals, consumer products, housing, construction, electronics, and health care primarily in Japan. Segments Chemicals The Chemicals Segment offers organic and inorganic industrial chemicals, synthetic resin, synthetic rubber, high-compound fertilizer, coating materials, latex, pharmaceutical and food additives, explosives, photopolymers and platemaking systems, separation and ion-exchange membranes, systems, and equipment. The company produces, processes, and sells chemicals and derivative products, such as ammonia, nitric acid, caustic soda, acrylonitrile, styrene monomer, methyl methacrylate (MMA) monomer, PMMA resin, high-compound fertilizers, and adipic acid; polymer products, such as Suntec polyethylene (PE), Stylac-AS (styrene-acrylonitrile), Stylac-ABS (acrylonitrile-butadiene-styrene), synthetic rubber, Tenac polyacetal, Xyron modified polyphenylene ether (mPPE), and Leona nylon 66 polymer and filament); and specialty products, such as coating materials, latex, Ceolus microcrystalline cellulose, explosives, explosion-bonded metal clad, APR photosensitive resin and printing plate making systems, Microza UF and MF membranes and systems, Hipore microporous membrane, ion-exchange membranes and electrolysis systems, Saran Wrap cling film, Ziploc storage bags, and plastic films, sheets, and foams.

Asahi Kasei

Big Idea Ventures is the world’s most active investor in FoodTech investing in the best food technology and agritech companies globally. The company is focused on alternative protein with its New Protein Fund and commercialization of university intellectual property with its Generation Food Rural Partners fund. BIV is backed by a strong network of strategic partners including AAK, Avril, Bühler, Givaudan, Temasek Holdings, and Tyson Ventures, and is partnering with governments around the world working on food security and new food ecosystems. The firm has offices in New York, Paris and Singapore and has invested in more than 100 companies across 22 countries. For more information, visit bigideaventures.com

Big Idea Ventures

SynBioVen is focused on supporting the next generation of synthetic biology scientists, founders and start-ups.

SynBioVen

Multus

Multus enables cultivated meat companies to scale affordably and profitably. They take care of the growth media, so its customers can focus on bringing delicious, sustainable meat to the world. Taking a machine learning-based approach they can design a completely animal-free growth media that is tailored for animal cells. This is particularly useful for the cultivated meat industry where there are needs of high performance at large scale. Multus was established in 2019 and is headquartered in London, England.

Multus, a spin-off of SOSV’s IndieBio program, is a biotechnology company that specializes in the development of growth media solutions for cellular agriculture applications. Its portfolio includes serum-free FBS alternatives (Proliferum M and Proliferum LSR) and solutions that support cell adhesion (rh-Vitronectin) during the cultivation process.

Making meat sustainable over the long term

Cell-cultured Meat

New Wave Biotech and Multus collaborate using AI to transform food production

Multus, a spin-off of SOSV’s IndieBio program, is a biotechnology company that specializes in the development of growth media solutions for cellular agriculture applications. Its portfolio includes serum-free FBS alternatives (Proliferum M and Proliferum LSR) and solutions that support cell adhesion (rh-Vitronectin) during the cultivation process.Multus leverages MediOp, a growth media formulation design platform, to develop its solutions. According to the company, this technology allows optimizing solutions using automated data analysis and insights. Multus also uses this platform to provide contract manufacturing services for custom formulation design and food-safe manufacturing compliant with ISO22000 to customers in North America, Europe, and Asia-Pacific. In December 2024, the company launched&nbsp;<a href="https://sp-edge.com/updates/37120">Proliferum B</a>, an animal component-free alternative to fetal bovine serum (FBS) for cultivated meat production.In <a href="https://sp-edge.com/updates/25572">January 2024</a>, the company unveiled what it claims to be the first large-scale production plant-making serum-free growth media in the cultivated meat industry.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/24911">December 2023</a>, the company partnered with New Wave Biotech, a bioprocess optimization software company, under a project funded through an Innovate UK Engineering Biology grant. Through this partnership, Multus planned to use New Wave Biotech’s AI software to optimize its process of developing precision-fermented ingredients for cell cultivation.&nbsp;

Mosa Meat is a Dutch cell-cultured meat startup founded by Dr. Mark Post of Maastricht University, and was the first-ever company to produce a lab-grown meat burger. The startup produces meat by growing myosatellite cells (muscle stem cells) extracted from an animal in a bioreactor fed with a nutrient-dense medium.The company replaced the fetal bovine serum (FBS) from its growth medium in July 2020, which led to an 88x cost reduction in its medium. As of March 2024, Mosa Meat operated the Center for Advanced Meat Production, Upscaling, and Sustainability (CAMPUS), a facility spanning over 79,000 sq ft that was designed to be expandable as demand grows.In <a href="https://sp-edge.com/updates/21645">September 2023</a>, Mosa Meat became the first cultivated meat company to attain B Corp certification. The company also announced plans to apply for regulatory approval in countries worldwide. In <a href="https://sp-edge.com/updates/21645">September 2023</a>, Mosa Meat became the first cultivated meat company to attain B Corp certification. The company also announced plans to apply for regulatory approval in countries worldwide. In <a href="https://sp-edge.com/updates/31970">July 2024</a>, it conducted the first official tasting of its cultivated beef product, the Mosa Burger, in the Netherlands. This event gathered Dutch cattle farmers, food product developers, and industry representatives to collect expert feedback.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/14175">November 2022</a>, Mosa Meat entered into an agreement with Singapore-based contract development and manufacturing organization (CDMO) Esco Aster to commercialize its cultivated beef in Singapore. Further, in <a href="https://sp-edge.com/updates/16845">March 2023</a>, the company partnered withNutreco to develop a cell feed supply chain that can expedite production and scalability while reducing cost.Funding and financialsIn its latest funding round in <a href="https://sp-edge.com/updates/28536">April 2024</a>, the company raised EUR 40 million (~USD 42.5 million) in an oversubscribed funding round co-led by Lowercarbon Capital and M Ventures, with participation from PHW Group, Invest-NL, LIOF, and LEF. The funds were earmarked for scaling production procedures, reducing production costs, and gearing up for commercialization.

Mosa Meat

SuperMeat is a cellular agriculture startup developing cultured chicken meat. The company uses chicken cells and claims to grow them in a culture medium free from antibiotics and contaminants to develop its products. SuperMeat also operates a test kitchen known as The Chicken. It is claimed to be the world’s first farm-to-fork facility where diners can observe the production of cultivated chicken.In <a href="https://sp-edge.com/updates/21733">September 2023</a>, The Orthodox Union (OU) certified SuperMeat’s cultivated chicken as “kosher.” Further, the OU and SuperMeat will collaborate on establishing guidelines for the industry.In&nbsp;<a href="https://sp-edge.com/updates/35765">November 2024</a>, the company announced it had achieved cost parity for its cultivated chicken and could produce it at at USD 11.79 per pound at scale, matching the price of premium US pasture-raised chicken.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/9319">March 2022</a>, SuperMeat signed an MoU with PHW to supply cultivated meat products including chicken, turkey, and duck to the European market. The company also <a href="https://sp-edge.com/updates/8997">partnered</a> with Ajinomoto to set up a joint venture to accelerate the commercialization of cultivated meat while focusing on developing a cost-competitive cell growth media.In <a href="https://sp-edge.com/updates/11867">July 2022</a>, the company signed an MoU with Switzerland’s largest retail supermarket chain and leading meat manufacturer, Migros to expedite production and distribution of cultured meat at a commercial scale with a focus on European markets.&nbsp;

SuperMeat

Uncommon (formerly HigherSteaks) is a UK-based cell-cultured meat startup that uses cellular agriculture to grow pork from animal cells. The company leverages cellular agriculture and in-house developed RNA technologies to cultivate meat and claims its technology eliminates the need for genetic engineering and growth media.In July 2020, the company unveiled the world's first lab-grown pork belly prototype and the second cell-based bacon (behind Mission Barns cell-based bacon unveiled in early 2020). The pork belly and the bacon were produced from a combination of cell-cultured muscle and plant-based proteins and fat. Uncommon plans to commercialize its cell-cultured meat by 2022-2025, pending regulatory approval.Funding and financialsIn <a href="https://sp-edge.com/updates/19267">June 2023</a>, the company raised USD 30 million in Series A funding co-led by Balderton Capital and Lower Carbon Capital, with participation from Redalpine, East Alpha, and others. The funds were earmarked for the development of its innovative approach, expanding production, increasing the team, and initiating regulatory approvals.

Uncommon

Based in Israel, Believer Meats (Future Meat Technologies prior to November 2022) develops hardware and cell lines for the manufacturing of cell-cultured meat, to commercialize its manufacturing hardware and techniques.Believer Meats uses fibroblast cells that can be triggered with small molecules to develop either fat or muscle cells. Fat and muscle cells are cultured in a unique bioreactor that removes the waste material from the media, allowing the company to recycle parts of the media to reduce feed media input by as much as 50%. The startup replaced FBS with molecules derived from Chinese hamster ovaries (CHO) to reduce production costs and plans to achieve price parity with animal counterparts.In <a href="https://sp-edge.com/updates/12623">August 2022</a>, the company announced it has developed what it claims to be the world’s first cultivated lamb, using cell lines isolated from Awassi sheep.In <a href="https://sp-edge.com/updates/15195">December 2022</a>, the company announced it has begun development of a 200,000 sq foot production facility in Wilson, North Carolina with an annual capacity of ~22 million lbs, which is claimed to be the largest cultivation facility in the world. Believer Meats plans to produce cultured chicken, pork, beef, and lamb for US, European, and Asian markets.Key customers and partnershipsIn March 2022, the company <a href="https://sp-edge.com/updates/9320">partnered</a> with Charoen Pokphand Foods to develop cultivated meat products for Asia.In <a href="https://sp-edge.com/updates/17710">April 2023</a>, Believer Meats signed an MoU with Archer Daniels Midland (ADM) to collaborate on the development and commercialization of cultivated meat products. Further, ADM will offer its ingredient pantry and nutrition knowledge to enhance Believer's cell-cultivated meat process.In <a href="https://sp-edge.com/updates/30520">June 2024,</a> Believer Meats partnered with Abu Dhabi’s AgriFood Growth &amp; Water Abundance (AGWA), to advance cultivated meat production in the MENA region.&nbsp;&nbsp;

Believer Meats

Producers of cell-cultured seafood using cells extracted from fish. Startups have succeeded in developing prototypes of yellowtail and salmon

Producers of cell-cultured pork using cells extracted from animals. Startups have succeeded in developing prototypes of bacon and pork belly using cultured muscle and plant-based proteins and fat

Producers of cell-cultured beef using cells extracted from animals. Some producers in the industry are developing premium beef ranges such as Wagyu. Startups have only succeeded in developing prototypes in the minced form, with a few creating prototypes of (pieces of) steak using 3D bioprinters

Producers of cell-cultured chicken and duck using cells extracted from animals. Some producers in the industry are developing rare delicacies such as foie gras. Startups have only succeeded in developing products in the nugget form

Producers of growth media for cell-cultured meat production and ingredients for meat and meat analog (cell-cultured, plant-based) producers, which can include cell culture meat paste, culture fat, etc. Producers of growth media mainly focus on developing alternative growth media to FBS using plant-based or other sources

Developers of bioreactors and other technologies used in cell-cultured meat production. Industrial scaling and efficiency gains are key areas of interest for startups in the industry

Provide sustainable solutions for animal slaughter through the use of biotechnology

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 Multus, a British biotech company, has unveiled a product called Proliferum B, an alternative to fetal bovine serum (FBS) especially designed for cultivated meat production. The product was created via a machine learning-driven system and it is ready to be sampled upon request.
 Proliferum B is made to replace FBS in cell culture processes and it has been developed specifically using bovine cells. The product underwent a series of tests against FBS using a variety of cell types such as primary bovine fibroblasts, immortalized bovine satellite cells, and immortalized murine pre-adipocytes. The results demonstrated a significantly decreased doubling time and a consistent performance over several passages.
 The main aim of Proliferum B is to tackle problems related to high costs, lack of reliability, and ethical concerns that are associated with FBS, further helping to accelerate the early stages of research and development. Multus developed this product within nine months from lab to market, asserting that it will assist cultivated meat companies in scaling faster and aid in making cultivated meat more affordable and easily accessible.
</div> Analyst QuickTake: 
 In <a href="https: 
//sp-edge.com/updates/25572"> January 2024 </a> , the company unveiled what it claims to be the first large-scale production plant making serum-free growth media in the cultivated meat industry. Further, in <a href="https: 
//sp-edge.com/updates/24911"> December 2023 </a> , it partnered with New Wave Biotech to advance cultivated meat production with AI. The combination of these developments was likely instrumental in the development of the new serum.

Multus

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless